Literature DB >> 10820239

CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.

E V Fedoseyeva1, F Boisgérault, N G Anosova, W S Wollish, P Arlotta, P E Jensen, S J Ono, G Benichou.   

Abstract

We analyzed CD4+ T helper responses to wild-type (wt) and mutated (mut) p53 protein in normal and tumor-bearing mice. In normal mice, we observed that although some self-p53 determinants induced negative selection of p53-reactive CD4+ T cells, other p53 determinants (cryptic) were immunogenic. Next, BALB/c mice were inoculated with J774 syngeneic tumor cell line expressing mut p53. BALB/c tumor-bearing mice mounted potent CD4+ T cell responses to two formerly cryptic peptides on self-p53. This response was characterized by massive production of IL-5, a Th2-type lymphokine. Interestingly, we found that T cell response was induced by different p53 peptides depending upon the stage of cancer. Mut p53 gene was shown to contain a single mutation resulting in the substitution of a tyrosine by a histidine at position 231 of the protein. Two peptides corresponding to wt and mutated sequences of this region were synthesized. Both peptides bound to the MHC class II-presenting molecule (Ed) with similar affinities. However, only mut p53.225-239 induced T cell responses in normal BALB/c mice, a result strongly suggesting that high-affinity wt p53.225-239 autoreactive T cells had been eliminated in these mice. Surprisingly, CD4+ T cell responses to both mut and wt p53.225-239 peptides were recorded in J774 tumor-bearing mice, a phenomenon attributed to the recruitment of low-avidity p53.225-239 self-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820239     DOI: 10.4049/jimmunol.164.11.5641

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

2.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

3.  CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Goro Takahashi; Atsushi Okamoto; Nobuhiko Furuya; Theresa L Whiteside; Albert B DeLeo; Keisuke Masuyama
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

4.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

5.  Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model.

Authors:  Ana P Castano; Pawel Mroz; Mei X Wu; Michael R Hamblin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

6.  Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.

Authors:  Zheng-Cai Jia; Bing Ni; Ze-Min Huang; Yi Tian; Jun Tang; Jing-Xue Wang; Xiao-Lan Fu; Yu-Zhang Wu
Journal:  Clin Dev Immunol       Date:  2011-02-14

Review 7.  Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.

Authors:  Erin Flynt; Kamlesh Bisht; Vinidhra Sridharan; María Ortiz; Fadi Towfic; Anjan Thakurta
Journal:  Cells       Date:  2020-01-24       Impact factor: 6.600

Review 8.  The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.

Authors:  A P B Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.